Journal of Oncology Pharmacy Practice最新文献

{"title":"Decreasing insulin induced hypoglycemia with education of a new multimodal hyperkalemia order set for patients admitted to a cancer center.","authors":"Anoop Kotian, Katherine E Cain, Tanner Moser, Rina Patel, Mary Lou Warren, Sonali N Thosani","doi":"10.1177/10781552251356915","DOIUrl":"https://doi.org/10.1177/10781552251356915","url":null,"abstract":"<p><p>IntroductionThis study aimed to reduce hypoglycemia by 25% in patients receiving intravenous insulin therapy for hyperkalemia through a new multimodal treatment order set. Historically, the hypoglycemia rate with the previous single-agent order set was 12.1%. Given the high-risk nature of the oncology population, even one episode of hypoglycemia can increase morbidity and negatively impact clinical outcomes.MethodsBetween October 1st and November 30th, 2023, educational materials on the new order set were presented to advanced practice practitioners, hospital physician leadership, and nursing groups. Postintervention data were collected retrospectively from December 1st, 2023, to January 22nd, 2024, using electronic health records of patients who received intravenous insulin and dextrose 50% (D50%) per the new order set. A manual chart review assessed compliance and the rate of hypoglycemia (blood glucose <70 mg/dL). Insulin dosing compliance followed weight-based dosing (0.1 units/kg, max 10 units), and D50% dosing was based on baseline point-of-care (POC) BG levels (25G if POC BG 140-250 mg/dL and 50G if <140 mg/dL).ResultsOf 125 encounters reviewed, 91 (73%) received intravenous insulin. The hypoglycemia rate was 6%, with no severe hypoglycemia (<40 mg/dL). The median baseline POC BG, creatinine clearance, and patient weight were 132.5 mg/dL, 51 mL/min, and 73 kg, respectively. All insulin doses were compliant, and 81% of D50% doses adhered to guidelines.ConclusionThe new multimodal treatment order set led to a 45.5% reduction in hypoglycemia. Provider education and standardized protocols were key in enhancing patient safety during hyperkalemia management.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251356915"},"PeriodicalIF":0.9,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144731872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast and colon cancer knowledge among community pharmacists in Yemen: A cross-sectional study.","authors":"Gamal Esam Ahmed Alsakkaf, Ahmed Mohammed Ali Abdulkhaleq","doi":"10.1177/10781552251360633","DOIUrl":"https://doi.org/10.1177/10781552251360633","url":null,"abstract":"<p><p>BackgroundBreast and colon cancer are the most common types of cancer among cancer patients worldwide. Therefore, health practitioners, particularly community pharmacists, should be well-informed about breast and colon cancer. Proper education background and knowledge offer significant advantages, from early diagnosis to treatment, especially in poor countries that are suffering from conflicts and crises that have influenced healthcare services, such as Yemen.MethodologyThis cross-sectional study was conducted in Yemen between 1 May 2024 and 30 August 2024. It aims to assess community pharmacists' knowledge of breast and colon cancer in Yemen.ResultA total of 600 community pharmacists participated in this study. Twenty-five incompletely filled questionnaires were excluded from the study. Regarding community pharmacists' knowledge of breast cancer, 356 out of 575 had good knowledge, and 219 out of 575 had poor knowledge. Regarding community pharmacists' knowledge of colon cancer, 327 out of 575 had good knowledge, and 248 out of 575 had poor knowledge. The total scores of knowledge community pharmacists about breast and colon cancer were 7.55 ± 2.48 and 6.60 ± 2.81, respectively.ConclusionsThe findings of the study indicate that most community pharmacists possess a good understanding of the risk factors and symptoms associated with breast and colon cancer. However, their knowledge does not meet the ideal level expected in the fight against cancer. We suggest that future studies also evaluate pharmacists' knowledge about other types of cancer.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251360633"},"PeriodicalIF":1.0,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144707773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics of adverse drug reactions resulting in modifications of antineoplastic therapy plan in patients with breast cancer at a comprehensive cancer center.","authors":"Saba Marji, Raghad Tawalbeh, Amal AlJammal, Ola Mashni, Nour Faqeer","doi":"10.1177/10781552251362378","DOIUrl":"https://doi.org/10.1177/10781552251362378","url":null,"abstract":"<p><p>IntroductionAdherence to standard antineoplastic treatment is associated with improved response in breast cancer patients. However, treatment modifications may be necessary for patients who experience significant adverse drug reactions (ADRs). Limited data exist on the characteristics of ADRs that require such modifications. We aimed to evaluate significant ADRs associated with antineoplastic agents in breast cancer patients.MethodsA retrospective observational study was conducted at King Hussein Cancer Center, included significant ADRs experienced by breast cancer patients between January 2018 and December 2020. We recorded patients' characteristics, medications involved, the type of ADRs, and the required treatment modifications, including dose reduction, treatment delay, or discontinuation. Descriptive analysis was performed to report the results.ResultsDuring the study period, 597 significant ADRs were reported in 351 patients, with a mean age of 53 years (11.8 SD). Additionally, 65.5% of patients presented with locally advanced disease. Docetaxel (44%) was the most common agent associated with ADRs. Hematologic and gastrointestinal ADRs were the most frequently reported, accounting for 38.0% and 18.0% of ADRs, respectively. Of the reported ADRs, 61.0%, 26.0%, 13.0% resulted in treatment dose reduction, delay and discontinuation of subsequent cycle, respectively.ConclusionIn this study evaluating a relatively large number of significant ADRs, docetaxel was the most common antineoplastic agent requiring treatment modifications. The most frequent modification was dose reduction. Future studies should be directed to identify measures that may reduce the incidence and severity of the ADRs.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251362378"},"PeriodicalIF":1.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of oncology drugs prescriptions and pharmacist interventions at an oncology and hematology service.","authors":"Gabriel Catarino, Mariana Barbosa Ribeiro Gomes, Gabriela Reis Pereira-Oliveira, Karoline Alvellos Borella, Marcio Luis Lima Borella, Claudiana de Jesus Felismino","doi":"10.1177/10781552251360944","DOIUrl":"https://doi.org/10.1177/10781552251360944","url":null,"abstract":"<p><p>IntroductionThe evaluation of antineoplastic drug prescriptions by oncology pharmacists represents a critical step in ensuring safe and effective cancer treatment. This process requires access to essential and readily available patient and treatment information, which facilitates accurate protocol validation, dose calculation, drug preparation, and identification of discrepancies requiring intervention.MethodsA cross-sectional, retrospective study was conducted at a Brazilian military hospital to analyze antineoplastic prescriptions of patients treated between November 2020 and June 2021. Data analysis was performed in September 2021. The primary objective was to quantify pharmaceutical interventions performed during prescription evaluation.ResultsA total of 299 prescriptions were reviewed. Among these, 33% (n = 98) lacked information on the patient's date of birth, 45.8% (n = 137) did not include International Classification of Diseases (ICD) codes, 87% (n = 260) were missing data on treatment cycles, and 93% (n = 278) lacked cancer staging information. Pharmaceutical interventions were required in 195 prescriptions (65.2%), with the majority (64.1%; n = 125) related to the omission of drug infusion times.ConclusionsPharmaceutical interventions in the evaluation of antineoplastic prescriptions played a pivotal role in enhancing treatment accuracy and safety. The findings underscore the need for process optimization and system improvements to ensure complete and standardized prescriptions, ultimately contributing to safer oncology practices.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251360944"},"PeriodicalIF":1.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144698872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pharmacists at the frontline: A cross-sectional study of knowledge, attitudes, and barriers to breast cancer screening promotion in Saudi Arabia.","authors":"Fahad Alzahrani, Norah S Alotaibi, Shatha A Albishi, Norah M Alnefaie, Ahad A Alharbi, Silwan A Maash, Hanan T Alosaimi, Haifa A Fadil, Faris S Alnezary","doi":"10.1177/10781552251360206","DOIUrl":"https://doi.org/10.1177/10781552251360206","url":null,"abstract":"<p><p>BackgroundBreast cancer remains a major public health concern in Saudi Arabia, with low screening rates and late-stage diagnoses. Community pharmacists are accessible healthcare providers who could play a key role in promoting breast cancer screening. However, little is known about their knowledge, attitudes, and perceived barriers related to screening promotion. This study aimed to assess Saudi community pharmacists' knowledge, attitudes, and barriers related to breast cancer screening promotion and to identify predictors of higher knowledge levels.MethodsA cross-sectional study was conducted among 382 community pharmacists in Saudi Arabia using a validated, structured questionnaire. The survey assessed demographic information, knowledge of breast cancer, attitudes toward screening promotion, and perceived barriers. Data were analyzed using Chi-square tests, Spearman's correlation, and logistic regression.ResultsAlthough 73.6% of pharmacists achieved knowledge scores ≥ 50% (answering more than 11 out of 23 questions correctly), A considerable proportion (41.3%) incorrectly believed that breast size is associated with cancer risk. While pharmacists generally exhibited positive attitudes, about 30% did not view breast cancer screening promotion as part of their role. Significant barriers included the availability of enough personnel, having sufficient time for counseling, and access to educational materials. Logistic regression identified seeing fewer female patients and not attending cancer awareness events as predictors of lower knowledge.ConclusionsDespite moderate knowledge and positive attitudes, structural and educational barriers hinder pharmacists' active involvement in breast cancer screening promotion. Targeted educational initiatives, better resource access, and integration into national screening strategies are essential to optimize pharmacists' contributions to early detection efforts.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251360206"},"PeriodicalIF":1.0,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144649718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment outcomes of hypercalcemia that resulting in hospital admission in cancer patients treated with bisphosphonates in real-world setting.","authors":"Tasnim Quran, Nour Maraqa, Joud Aqarbeh, Renad Abu-Khader, Ayah Habeeb, Nour Faqeer","doi":"10.1177/10781552251360327","DOIUrl":"https://doi.org/10.1177/10781552251360327","url":null,"abstract":"<p><p>Limited real-world studies have assessed bisphosphonates (BPs) treatment for hypercalcemia of malignancy (HCM) requiring hospital admission. We aimed to evaluate the response to BPs in terms of rate, timing and 30-day readmission. This retrospective study included adult cancer patients admitted to the hospital with hypercalcemia from January 2019 to August 2023. Medical records were reviewed to collect baseline characteristics and treatment outcomes of HCM, including complete remission (CR), defined as corrected serum calcium (CSC) normalization to 10.8 mg/dl or below, partial response (PR), defined as CSC trending down but not reaching 10.8 upon discharge, and readmission due to hypercalcemia within one month. During the study period, 505 patients were included, with a mean age of 58.2 years (± 12.5 SD); 52.3% were male, predominant cancers were breast 26.1% and lung 16.0%, with 53.9% having bone metastasis. Severe, moderate, and mild hypercalcemia were observed in 30.5%, 46.9%, and 22.6% patients, respectively. Zoledronic acid and pamidronate were administered to 75.4% and 24.6% patients, respectively. CR was achieved in 73.5% of patients, while 19.4% showed PR, and 2.6% had no response. Zoledronic acid led to faster CSC normalization (2.6 days ± 1.5 SD) compared to pamidronate (3.9 days ± 2.4 SD) (P = 0.001). Additionally, 13.7% of patients required readmission due to hypercalcemia, with a significantly lower rate associated with zoledronic acid compared to pamidronate (P = 0.042). While BPs were effective in achieving CR in most patients, a remarkable fraction required readmission, highlighting the need for additional research to identify factors predisposing patients to recurrent hypercalcemia.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251360327"},"PeriodicalIF":1.0,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144659486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of bevacizumab on port catheter complications: A retrospective evaluation in cancer patients.","authors":"Gökhan Karakaya, Zeliha Koca, Hasan Şenol Coşkun","doi":"10.1177/10781552251357197","DOIUrl":"https://doi.org/10.1177/10781552251357197","url":null,"abstract":"<p><p>AimTo retrospectively compare port catheter-related complications in chemotherapy patients with and without bevacizumab treatment, and to identify additional factors contributing to these complications.MethodsThis retrospective study included cases who received chemotherapy with a port catheter between January 2014 and May 2018 at our hospital. The study retrospectively collected data on patient demographics, malignancy details, comorbidities, chemotherapy drugs, catheter insertion timing, complications, removal reasons, neutropenia, culture results, and patient outcomes. Patients were grouped based receiving or not receiving bevacizumab in combination with chemotherapy.ResultsThe study included 600 patients, 227 of whom received chemotherapy combined with bevacizumab. The results showed that leukemia was significantly associated with an increased risk of catheter complications (p < 0.001), while the presence of any comorbidity was independently linked to a decreased risk of complications (p = 0.030). In patients receiving bevacizumab, complications occurred more frequently when the catheter was placed simultaneously with the drug (p = 0.017). Additionally, the complication group had a significantly shorter catheter duration (p < 0.001) and a higher mortality rate (p = 0.037). Multivariable logistic regression analysis revealed that leukemia was a significant independent factor for increased complication risk (p < 0.001), while comorbidities were protective against complications (p = 0.030).ConclusionBevacizumab was associated with increased complication risk in only subjects in which treatment was initiated immediately after catheter placement. However, multivariable analysis revealed that this significant relationship disappeared when adjusted for other factors, leaving leukemia as the only risk factor independently associated with port catheter complications.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251357197"},"PeriodicalIF":1.0,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of adverse drug reactions among acute myeloid leukaemia patients at Kenyatta National Hospital.","authors":"Mari Heho, Amsalu Degu, Calvin A Omolo","doi":"10.1177/10781552251352453","DOIUrl":"https://doi.org/10.1177/10781552251352453","url":null,"abstract":"<p><p>BackgroundAcute Myeloid leukaemia (AML) chemotherapy is linked to a considerable adverse drug reaction (ADRs). However, data regarding the ADRs in AML patients receiving chemotherapy in Kenya is scarce. This study aimed to assess the adverse drug reactions among AML patients treated at Kenyatta National Hospital (KNH).MethodsA one-arm retrospective cohort study design was used to assess ADRs among eligible AML patients who received treatment at KNH between 1st January 2018 and 31st December 2023. A data abstraction tool was used to collect socio-demographics, comorbidities, the treatment regimen, and chemotherapy-related ADRs. The CTCAE v3.0 grading system and the modified Schumock and Thornton Scale were used to evaluate the severity and preventability of ADRs, respectively. The data collected was analysed using the SPSS version 29.0.01 software. Mean and median were used to report the age of participants, while other socio-demographic variables and adverse drug reactions were reported as percentages and frequencies.ResultsThe prevalence of ADRs in this study was 96.7%, with a total of 123 ADRs recorded. The main adverse reactions observed were neutropenia (18%), thrombocytopenia (16.3%), anaemia (14.6%), and liver damage (10.6%). The majority of the ADRs recorded were of moderate severity (40.7%) and non-preventable (59.3%).ConclusionThe prevalence of ADRs in AML patients was high. The most frequently reported ADR was neutropenia. The majority of ADRs were moderate severity level and non-preventable.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251352453"},"PeriodicalIF":1.0,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive risk factors associated with cancer therapy-related cardiac dysfunction: A retrospective cohort study.","authors":"Bruna Brito Machado, Andreia Biolo, Fernando Pivatto Júnior, Alana de Quadros Schroeder, Marco Aurélio Lumertz Saffi","doi":"10.1177/10781552251358183","DOIUrl":"https://doi.org/10.1177/10781552251358183","url":null,"abstract":"<p><p>IntroductionThe increasing cardiovascular events in cancer patients underscore the importance of identifying preexisting risk factors as predictors of heart disease outcomes. This study aimed to assess the predictive risk factors associated with cancer therapy-related cardiac dysfunction (CTRCD) in female patients with breast cancer undergoing treatment with anthracyclines and/or anti-HER-2 therapies.MethodsA cohort study was conducted at a university hospital outpatient clinic from 2019 to 2024. CTRCD was defined according to the European Society of Cardiology criteria as an absolute LVEF reduction of >10 percentage points to <50% during treatment.ResultsA total of 161 female patients were analyzed (mean age: 51.2 ± 11.6 years), with most being white/Caucasian (83.8%). The most prevalent cardiovascular risk factors were hypertension (47.2%), obesity (31.7%), smoking (31.0%), dyslipidemia (14.3%), and type 2 diabetes mellitus (12.4%). CTRCD occurred in 18 patients (11.1%), with a markedly higher prevalence (27.3%) in those with four or more cardiovascular risk factors. The median time (IQR) from the initiation of chemotherapy to CTRCD was 395 (248-674) days. Multivariable analysis identified the Charlson comorbidity index (HR 1.2; 95% CI: 1.0-1.4), chemotherapy duration (HR 1.0; 95%CI: 1.0-1.0) and LVEF before (HR 0.8; 95%CI: 0.7-0.9) and after chemotherapy (HR 0.8; 95%CI: 0.8-0.9) as independent factors for CTRCD. Breast cancer patients had a 17.7% risk of developing CTRCD within the first two years of antineoplastic treatment.ConclusionHypertension, obesity, and smoking were the most prevalent cardiovascular risk factors. Independent predictors of CTRCD included the Charlson comorbidity index, chemotherapy duration, and LVEF before and after treatment.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251358183"},"PeriodicalIF":1.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637338","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Laryngopharyngeal dysesthesia as a possible clinical manifestation of a cytokine release reaction due to oxaliplatin.","authors":"Maria Cruz Torres Gorriz, Julián Borras Cuartero, Paula Viedma Ayllón, Jorge Molina Saera, Ernesto Enrique","doi":"10.1177/10781552251358672","DOIUrl":"https://doi.org/10.1177/10781552251358672","url":null,"abstract":"<p><p>IntroductionLaryngopharyngeal dysesthesia is considered an acute peripheral neuropathy secondary to oxaliplatin neurotoxicity.Case reportWe report a case of laryngopharyngeal dysesthesia that developed in a patient with colon adenocarcinoma after receiving her third cycle of oxaliplatin.Management & outcomeShe was treated with antihistamines, steroids, oxygen, and adrenaline and referred to the allergy department for investigation of a hypersensitivity reaction to the drug. Skin tests and tryptase extracted after the acute episode ruled out this possibility. However, the patient presented a slight elevation of interleukin 6, commonly observed in cytokine release reactions. The patient continued her oxaliplatin treatment with cautious administration and under the supervision of the allergist.DiscussionLaryngopharyngeal dysesthesia is part of oxaliplatin neurotoxicity and does not require discontinuation of the drug. However, in patients with severe laryngopharyngeal dysesthesia symptoms, it would be advisable to perform a differential diagnosis with hypersensitivity reactions and cytokine release reactions, whose management differs from neurotoxic reactions.</p>","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"10781552251358672"},"PeriodicalIF":1.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}